

Yuan-Hong Jiang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6161757/yuan-hong-jiang-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

799
citations

16
h-index

24
g-index

85
ext. papers

1,095
ext. citations

2.9
avg, IF

4.75
L-index

#	Paper	IF	Citations
78	Bladder Ultrastructure and Urinary Cytokine Abnormality in Patients with Recurrent Urinary Tract Infection and the Changes after Intravesical Platelet-Rich Plasma Injections.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
77	Therapeutic outcome of active management in male patients with detrusor underactivity based on clinical diagnosis and videourodynamic classification.. <i>Scientific Reports</i> , 2022 , 12, 362	4.9	0
76	Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection.. <i>International Neurourology Journal</i> , 2022 ,	2.6	2
75	Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome-A Comparative Study of Different Injection Number, Additives and Concentrations.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 853776	5.6	1
74	Effect of videourodynamic subtypes on treatment outcomes of female dysfunctional voiding.. <i>International Urogynecology Journal</i> , 2022 , 1	2	0
73	Treatment outcomes of detrusor underactivity in women based on clinical and videourodynamic characteristics.. <i>International Urology and Nephrology</i> , 2022 , 1	2.3	1
72	Diagnostic and prognostic value of urine biomarkers among women with dysfunctional voiding.. <i>Scientific Reports</i> , 2022 , 12, 6608	4.9	1
71	Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?. <i>Diagnostics</i> , 2022 , 12, 1093	3.8	1
70	Clinical Correlation of Bladder Electron Microscopic Characteristics in Patients with Detrusor Underactivity of Various Etiologies. <i>Biomedicines</i> , 2022 , 10, 1055	4.8	
69	Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomedicines</i> , 2022 , 10, 1149	4.8	1
68	Changes in the Ultrastructure of the Bladder Urothelium in Patients with Interstitial Cystitis after Intravesical Injections of Platelet-Rich Plasma. <i>Biomedicines</i> , 2022 , 10, 1182	4.8	0
67	Smaller bladder capacity and stronger bladder contractility in patients with ketamine cystitis are associated with elevated TRPV1 and TRPV4. <i>Scientific Reports</i> , 2021 , 11, 5200	4.9	3
66	Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis/bladder pain syndrome patients with Hunner's lesion and grade B glomerulation might be different from other types of patients. <i>International Journal of Urology</i> , 2021 , 28, 823-830	2.3	3
65	Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021 , 13, 440-447	1.9	0
64	Therapeutic Effects of Urethral Sphincter Botulinum Toxin A Injection on Dysfunctional Voiding with Different Videourodynamic Characteristics in Non-Neurogenic Women. <i>Toxins</i> , 2021 , 13,	4.9	1
63	Deficits of urothelial cell proliferation, cytoskeleton, and barrier function protein expressions in patients with recurrent and persistent urinary tract infections. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021 , 13, 203-209	1.9	0
62	Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm. <i>Scientific Reports</i> , 2021 , 11, 914	4.9	12

61	Therapeutic efficacy of biofeedback pelvic floor muscle exercise in women with dysfunctional voiding. <i>Scientific Reports</i> , 2021 , 11, 13757	4.9	4
60	Difference in electron microscopic findings among interstitial cystitis/bladder pain syndrome with distinct clinical and cystoscopic characteristics. <i>Scientific Reports</i> , 2021 , 11, 17258	4.9	1
59	Possible Association between Bladder Wall Morphological Changes on Computed Tomography and Bladder-Centered Interstitial Cystitis/Bladder Pain Syndrome. <i>Biomedicines</i> , 2021 , 9,	4.8	3
58	Clinical Relevance of Bladder Histopathological Findings and Their Impact on Treatment Outcomes among Patients with Interstitial Cystitis/Bladder Pain Syndrome: An Investigation of the European Society for the Study of Interstitial Cystitis Histopathological Classification. <i>Journal of Urology</i> , 2021 , 205, 226-235	2.5	7
57	Ultrastructural changes in the underactive bladder. <i>Tzu Chi Medical Journal</i> , 2021 , 33, 345-349	1.1	0
56	Role of videourodynamic study in precision diagnosis and treatment for lower urinary tract dysfunction. <i>Tzu Chi Medical Journal</i> , 2020 , 32, 121-130	1.1	0
55	Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction. <i>International Neurourology Journal</i> , 2020 , 24, 301-312	2.6	6
54	Fatalism of urinary bladder. <i>Neurourology and Urodynamics</i> , 2020 , 39, 470-471	2.3	
53	Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. <i>Scientific Reports</i> , 2020 , 10, 15218	4.9	11
52	Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 318, F1391-F1399	4.3	16
51	Molecular Characteristics of Underactive Bladder. <i>Current Bladder Dysfunction Reports</i> , 2019 , 14, 47-57	0.4	
50	Possible predictor of early recovery on urinary continence after laparoscopic radical prostatectomy - Bladder neck level and urodynamic parameters. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 237-243	3.2	1
49	Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 279-284	3.2	5
48	Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency. <i>Tzu Chi Medical Journal</i> , 2019 , 31, 135-143	1.1	6
47	Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019 , 11, O180-O185	1.9	0
46	Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019 , 11, 66-71	1.9	9
45	Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury. <i>Journal of the Formosan Medical Association</i> , 2019 , 118, 125-133	3.2	1
44	Repeat retropubic suburethral sling procedure is effective for recurrent female stress urinary incontinence. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019 , 11, O89-O92	1.9	3

43	Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2018 , 200, 590-596	2.5	12
42	Histopathological characteristics of ketamine-associated uropathy and their clinical association. <i>Neurourology and Urodynamics</i> , 2018 , 37, 1764-1772	2.3	12
41	Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxinA injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial. <i>Neurourology and Urodynamics</i> , 2018 , 37, 1467-1473	2.3	7
40	Role of Bladder Dysfunction in Men with Lower Urinary Tract Symptoms Refractory to Alpha-blocker Therapy: A Video-urodynamic Analysis. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018 , 10, 32-37	1.9	7
39	Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment. <i>PLoS ONE</i> , 2018 , 13, e0190704	3.7	9
38	Urothelial Dysfunction and Chronic Inflammation are Associated With Increased Bladder Sensation in Patients With Chronic Renal Insufficiency. <i>International Neurourology Journal</i> , 2018 , 22, S46-54	2.6	9
37	Detrusor Underactivity and Bladder Outlet Procedures in Men. <i>Current Bladder Dysfunction Reports</i> , 2018 , 13, 274-281	0.4	2
36	Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. <i>Neurourology and Urodynamics</i> , 2018 , 37, 2651-2657	2.3	13
35	Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. <i>PLoS ONE</i> , 2018 , 13, e0198816	3.7	21
34	Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2017 , 9, 27-32	1.9	9
33	Urothelial Dysfunction and Chronic Inflammation in Diabetic Patients with Overactive Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2017 , 9, 151-156	1.9	9
32	Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxinA injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center. <i>Neurourology and Urodynamics</i> , 2017 , 36, 142-147	2.3	16
31	Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. <i>Neurourology and Urodynamics</i> , 2017 , 36, 338-343	2.3	3
30	Video-urodynamic characteristics of non-neurogenic, idiopathic underactive bladder in men - A comparison of men with normal tracing and bladder outlet obstruction. <i>PLoS ONE</i> , 2017 , 12, e0174593	3.7	13
29	Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery. <i>International Urology and Nephrology</i> , 2017 , 49, 1763-1770	2.3	8
28	Urothelial Barrier Deficits, Suburothelial Inflammation and Altered Sensory Protein Expression in Detrusor Underactivity. <i>Journal of Urology</i> , 2017 , 197, 197-203	2.5	31
27	Current pharmacological and surgical treatment of underactive bladder. <i>Tzu Chi Medical Journal</i> , 2017 , 29, 187-191	1.1	6
26	Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence 2017 , 29, 72-78		2

25	Therapeutic Efficacy of a New Procedure for Male Urinary Incontinence Combining a Suburethral Polypropylene Mesh and Cardiovascular Patch. <i>International Neurourology Journal</i> , 2017 , 21, 38-45	2.6	4
24	Long-term Outcomes of Augmentation Enterocystoplasty in Patients With End-Stage Bladder Diseases: A Single-Institute Experience Involving 102 Patients. <i>International Neurourology Journal</i> , 2017 , 21, 133-138	2.6	7
23	Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. <i>Neurourology and Urodynamics</i> , 2016 , 35, 609-14	2.3	75
22	Long-term follow up and predictive factors for successful outcome of transurethral incision of the bladder neck in women with detrusor underactivity. <i>Journal of the Formosan Medical Association</i> , 2016 , 115, 807-13	3.2	15
21	Urothelial Dysfunction, Suburothelial Inflammation and Altered Sensory Protein Expression in Men with Bladder Outlet Obstruction and Various Bladder Dysfunctions: Correlation with Urodynamics. <i>Journal of Urology</i> , 2016 , 196, 831-7	2.5	15
20	Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis. <i>PLoS ONE</i> , 2016 , 11, e0151692	3.7	16
19	Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility. <i>Toxins</i> , 2016 , 8,	4.9	16
18	Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery. <i>Toxins</i> , 2016 , 8, 91	4.9	9
17	OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction - A Randomized, Double-Blind, Placebo-Controlled Study. <i>Scientific Reports</i> , 2016 , 6, 38905	4.9	13
16	Practical points in the medical treatment of overactive bladder and nocturia in the elderly. <i>Tzu Chi Medical Journal</i> , 2016 , 28, 1-5	1.1	3
15	The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis: An Immunohistochemical Study. <i>Pain Physician</i> , 2016 , 19, E581-7	1.8	8
14	Current and potential urological applications of botulinum toxin A. <i>Nature Reviews Urology</i> , 2015 , 12, 519-33	5.5	21
13	5 α Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level. <i>Journal of the Formosan Medical Association</i> , 2015 , 114, 865-71	3.2	6
12	Urothelial dysfunction and chronic inflammation in patients with spinal cord injuries at different levels and correlation with urodynamic findings. <i>Neurourology and Urodynamics</i> , 2015 , 34, 757-62	2.3	14
11	Role of Bladder Neck and Urethral Sphincter Dysfunction in Men with Persistent Bothersome Lower Urinary Tract Symptoms after α 1 Blocker Treatment. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2015 , 7, 143-8	1.9	7
10	Alteration of Urothelial Inflammation, Apoptosis, and Junction Protein in Patients with Various Bladder Conditions and Storage Bladder Symptoms Suggest Common Pathway Involved in Underlying Pathophysiology. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2015 , 7, 102-7	1.9	38
9	Elevated serum IgE may be associated with development of ketamine cystitis. <i>Journal of Urology</i> , 2014 , 192, 1249-56	2.5	36
8	Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid. <i>PLoS ONE</i> , 2014 , 9, e91609	3.7	23

7	Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. <i>PLoS ONE</i> , 2014 , 9, e105989	3.7	22
6	Urothelial dysfunction and increased suburothelial inflammation of urinary bladder are involved in patients with upper urinary tract urolithiasis--clinical and immunohistochemistry study. <i>PLoS ONE</i> , 2014 , 9, e110754	3.7	3
5	Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity. <i>Neurourology and Urodynamics</i> , 2014 , 33, 1235-9	3.7	22
4	Positioning of a suburethral sling at the bladder neck is associated with a higher recurrence rate of stress urinary incontinence. <i>Journal of Ultrasound in Medicine</i> , 2013 , 32, 239-45	2.9	23
3	Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. <i>PLoS ONE</i> , 2013 , 8, e76779	3.7	69
2	International Prostatic Symptom Score-voiding/storage subscore ratio in association with total prostatic volume and maximum flow rate is diagnostic of bladder outlet-related lower urinary tract dysfunction in men with lower urinary tract symptoms. <i>PLoS ONE</i> , 2013 , 8, e59176	3.7	18
1	High classification of chronic heart failure increases risk of overactive bladder syndrome and lower urinary tract symptoms. <i>Urology</i> , 2012 , 79, 260-5	1.6	21